Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management

Influenza Other Respir Viruses. 2015 Jan;9(1):20-31. doi: 10.1111/irv.12293. Epub 2014 Nov 15.


This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.

Keywords: Antivirals; clinical management; immunocompromised; influenza; respiratory; treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Communicable Diseases, Emerging
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology
  • Humans
  • Immunocompromised Host
  • Influenza Vaccines
  • Influenza, Human* / drug therapy
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Influenza, Human* / virology
  • Middle East Respiratory Syndrome Coronavirus
  • Pandemics
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / epidemiology
  • Respiratory Tract Infections* / drug therapy
  • Respiratory Tract Infections* / epidemiology
  • Respiratory Tract Infections* / prevention & control
  • Respiratory Tract Infections* / virology
  • Virus Diseases* / drug therapy
  • Virus Diseases* / epidemiology
  • Virus Diseases* / virology


  • Antiviral Agents
  • Influenza Vaccines